Pharmhouse Corp (PHSE) - Net Assets

Latest as of March 2026: $54.93 Million USD

Based on the latest financial reports, Pharmhouse Corp (PHSE) has net assets worth $54.93 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($63.16 Million) and total liabilities ($8.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Pharmhouse Corp tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets $54.93 Million
% of Total Assets 86.97%
Annual Growth Rate 7.51%
5-Year Change 707.73%
10-Year Change 922937.24%
Growth Volatility 18761.76

Pharmhouse Corp - Net Assets Trend (1996–2025)

This chart illustrates how Pharmhouse Corp's net assets have evolved over time, based on quarterly financial data. See PHSE defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Pharmhouse Corp (1996–2025)

The table below shows the annual net assets of Pharmhouse Corp from 1996 to 2025. For live valuation and market cap data, see Pharmhouse Corp (PHSE) total market value.

Year Net Assets Change
2025-12-31 $52.30 Million +5309.87%
2024-12-31 $-1.00 Million -324.39%
2023-12-31 $-236.54K -106.72%
2022-12-31 $3.52 Million -45.60%
2021-12-31 $6.47 Million +1.74%
2020-12-31 $6.36 Million +32431.48%
2019-12-31 $-19.68K -7.62%
2018-12-31 $-18.29K -4.93%
2017-12-31 $-17.43K -407.62%
2015-12-31 $5.67K +56616.72%
2014-12-31 $9.99 -100.00%
1998-12-31 $570.54K -83.87%
1997-12-31 $3.54 Million -44.83%
1996-12-31 $6.41 Million --

Equity Component Analysis

This analysis shows how different components contribute to Pharmhouse Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 4184.6% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $3.87 Million 7.40%
Other Comprehensive Income $136.82K 0.26%
Other Components $72.24 Million 138.12%
Total Equity $52.30 Million 100.00%

Pharmhouse Corp Competitors by Market Cap

The table below lists competitors of Pharmhouse Corp ranked by their market capitalization.

Company Market Cap
D&C Media Co.Ltd
KQ:263720
$76.38 Million
PJBumi Bhd
KLSE:7163
$76.38 Million
Rock Tech Lithium Inc
V:RCK
$76.39 Million
Noble Development Public Company Limited
BK:NOBLE
$76.40 Million
Foshan Electrical and Lighting Co Ltd
SHE:200541
$76.37 Million
Taekyung BK Co Ltd
KO:014580
$76.36 Million
GeeCee Ventures Limited
NSE:GEECEE
$76.32 Million
Sena Development Public Company Limited
BK:SENA
$76.30 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Pharmhouse Corp's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from -1,003,849 to 52,299,290, a change of 53,303,139.
  • Net loss of 9,419,749 reduced equity.
  • New share issuances of 306,600 increased equity.
  • Other comprehensive income increased equity by 136,824.
  • Other factors increased equity by 62,279,464.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-9.42 Million -18.01%
Share Issuances $306.60K +0.59%
Other Comprehensive Income $136.82K +0.26%
Other Changes $62.28 Million +119.08%
Total Change $- %

Book Value vs Market Value Analysis

This analysis compares Pharmhouse Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.76x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 42.42x to 1.76x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1998-12-31 $0.00 $0.06 x
2014-12-31 $0.00 $0.06 x
2015-12-31 $0.00 $0.06 x
2017-12-31 $0.00 $0.06 x
2018-12-31 $0.00 $0.06 x
2019-12-31 $0.00 $0.06 x
2020-12-31 $0.07 $0.06 x
2021-12-31 $0.07 $0.06 x
2022-12-31 $0.04 $0.06 x
2023-12-31 $0.00 $0.06 x
2024-12-31 $0.00 $0.06 x
2025-12-31 $0.03 $0.06 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Pharmhouse Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -18.01%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -312.04%
  • • Asset Turnover: 0.05x
  • • Equity Multiplier: 1.15x
  • Recent ROE (-18.01%) is above the historical average (-65.30%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1996 -13.83% -7.20% 1.04x 1.85x $-1.53 Million
1997 -85.72% -21.58% 1.62x 2.45x $-3.39 Million
1998 -637.14% -43.02% 2.45x 6.04x $-3.69 Million
2014 14.91% 6.65% 0.40x 5.57x $0.49
2015 -0.08% -0.03% 0.36x 7.19x $-571.04
2017 0.00% -30.94% 0.27x 0.00x $-373.00
2018 0.00% -39.57% 0.11x 0.00x $969.90
2019 0.00% 0.00% 0.00x 0.00x $574.30
2020 -85.15% 0.00% 0.00x 1.04x $-6.06 Million
2021 -5.32% 0.00% 0.00x 1.02x $-992.13K
2022 -83.81% 0.00% 0.00x 1.11x $-3.30 Million
2023 0.00% 0.00% 0.00x 0.00x $-2.31 Million
2024 0.00% 0.00% 0.00x 0.00x $-676.69K
2025 -18.01% -312.04% 0.05x 1.15x $-14.65 Million

Industry Comparison

This section compares Pharmhouse Corp's net assets metrics with peer companies in the Lodging industry.

Industry Context

  • Industry: Lodging
  • Average net assets among peers: $2,221,170,381
  • Average return on equity (ROE) among peers: 11.04%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Pharmhouse Corp (PHSE) $54.93 Million -13.83% 0.15x $76.38 Million
Atour Lifestyle Holdings Limited American Depositary Shares (ATAT) $564.62 Million 25.69% 2.98x $3.73 Billion
Choice Hotels International Inc (CHH) $-23.51 Million 0.00% 0.00x $4.94 Billion
Civeo Corp (CVEO) $303.70 Million 1.32% 0.86x $360.36 Million
GreenTree Hospitality Group Ltd (GHG) $1.86 Billion 21.15% 0.62x $74.07 Million
Hyatt Hotels Corporation (H) $4.83 Billion 2.34% 0.55x $8.28 Billion
Hilton Worldwide Holdings Inc (HLT) $-819.00 Million 0.00% 0.00x $72.11 Billion
Huazhu Group Ltd (HTHT) $11.04 Billion -4.21% 4.73x $13.42 Billion
The Intergroup Corporation (INTG) $4.60 Million -32.61% 7.22x $79.25 Million
Marriott International Inc (MAR) $2.23 Billion 85.71% 9.65x $104.05 Billion

About Pharmhouse Corp

NASDAQ:PHSE USA Lodging
Market Cap
$138.03 Million
Market Cap Rank
#20360 Global
#4555 in USA
Share Price
$0.06
Change (1 day)
+15.83%
52-Week Range
$0.03 - $0.22
All Time High
$0.22
About

Pride Holdings Group operates as a LGBTQ-focused entertainment, hospitality, and lifestyle company in the United States. It engages in the bar, pub, tavern, restaurant, hotels, nightclubs, and live adult entertainment industry businesses. The company was formerly known as Parliament House Enterprises, Inc. and changed its name to Pride Holdings Group in July 2025. Pride Holdings Group is based in… Read more